Ascend Wellness Holdings (AAWH) Cash from Investing Activities (2020 - 2026)
Ascend Wellness Holdings' (AAWH) quarterly Cash from Investing Activities came in at -$4.8 million in Q1 2026, up 39.43% year-on-year from -$3.4 million in Q1 2025, and up 71.65% quarter-over-quarter from -$16.8 million in Q4 2025.
Ascend Wellness Holdings (AAWH) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Ascend Wellness Holdings' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$4.8 million for Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 39.43% year-over-year to -$4.8 million in Q1 2026; TTM through Mar 2026 was -$42.6 million, a 0.96% increase from a year earlier, with the FY2025 full-year figure at -$45.7 million, down 22.96% from the prior year.
- Cash from Investing Activities climbed to -$4.8 million in Q1 2026 per AAWH's latest filing, from -$16.8 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$622000.0 in Q1 2022 and bottomed at -$47.7 million in Q2 2022.
- The 5-year median for Cash from Investing Activities is -$11.1 million (2024), against an average of -$15.4 million.
- Across the five-year window, Cash from Investing Activities surged 98.23% in 2022 and sank 813.02% in 2023, its largest moves.
- Year by year, Cash from Investing Activities stood at -$19.7 million in 2022, then soared by 58.62% to -$8.2 million in 2023, then rose by 11.8% to -$7.2 million in 2024, then plunged by 133.08% to -$16.8 million in 2025, then soared by 71.65% to -$4.8 million in 2026.
- Per Business Quant, the three latest AAWH Cash from Investing Activities figures stand at -$4.8 million (Q1 2026), -$16.8 million (Q4 2025), and -$12.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Ascend Wellness Holdings | 78.95 Mn | 18.03 Mn | 44.88 Mn | -4.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.75 Mn |
| Mar 31, 2026 | -4.75 Mn |
| Dec 31, 2025 | -16.76 Mn |
| Dec 31, 2025 | -16.76 Mn |
| Sep 30, 2025 | -12.54 Mn |
| Sep 30, 2025 | -12.54 Mn |
| Jun 30, 2025 | -8.59 Mn |
| Jun 30, 2025 | -8.59 Mn |
| Mar 31, 2025 | -7.85 Mn |
| Mar 31, 2025 | -7.85 Mn |
| Dec 31, 2024 | -7.19 Mn |
| Dec 31, 2024 | -7.19 Mn |
| Sep 30, 2024 | -11.14 Mn |
| Sep 30, 2024 | -11.14 Mn |
| Jun 30, 2024 | -16.88 Mn |
| Jun 30, 2024 | -16.88 Mn |
| Mar 31, 2024 | -1.99 Mn |
| Mar 31, 2024 | -1.99 Mn |
| Dec 31, 2023 | -8.15 Mn |
| Dec 31, 2023 | -8.15 Mn |